Cagrilintide: Long-Acting Amylin Analogue, Mechanism, and Obesity Research

Cagrilintide is a long-acting, once-weekly analogue of amylin, a pancreatic hormone involved in satiety and post-meal glucose control. It is being developed by Novo Nordisk for chronic weight management, both on its own and in a fixed combination with semaglutide known as CagriSema. Cagrilintide matters clinically because it works through a different hormonal pathway from the GLP-1 class, which is why it is studied as a partner to semaglutide rather than a replacement. This page covers what the cagrilintide peptide is, how amylin signaling works, what published research has examined, and where it stands with regulators. Cagrilintide is an investigational drug: there is no FDA-approved cagrilintide product at the time of writing.

Amylin: The Hormone Cagrilintide Mimics

A Second Satiety Signal From the Pancreas

Amylin is a 37-amino-acid peptide hormone secreted by pancreatic beta cells together with insulin in response to a meal. Its effects complement insulin's:

• Slower gastric emptying, which moderates how quickly nutrients reach the small intestine
• Suppression of post-meal glucagon, which limits the liver's glucose output after eating
• Satiety signaling in the brainstem, including the area postrema, which contributes to earlier meal termination

People with type 1 diabetes produce little or no amylin, and amylin secretion is reduced in advanced type 2 diabetes. That observation is what first drove interest in amylin replacement.

From Pramlintide to a Once-Weekly Analogue

Native human amylin is not practical as a drug: it tends to aggregate and has a very short half-life. Pramlintide (Symlin), a soluble amylin analogue, was approved by the FDA in 2005 as a mealtime adjunct for people with type 1 or type 2 diabetes using insulin. Pramlintide established that the amylin pathway is clinically usable, but it requires injections with meals, several times a day.

Cagrilintide was engineered to remove that limitation. Structural modifications, including a lipid (acyl) side chain that promotes binding to albumin, extend its half-life enough to support once-weekly subcutaneous dosing, the same schedule as semaglutide and tirzepatide.

How Cagrilintide Works

Receptor Targets

Amylin acts on a family of receptors formed when the calcitonin receptor pairs with receptor activity-modifying proteins (RAMPs). Cagrilintide has been described as a nonselective agonist at amylin receptors and at the calcitonin receptor itself. The practical consequence is signaling in brain regions involved in appetite and satiety, particularly the hindbrain, with downstream effects on hypothalamic appetite circuits.

How It Differs From GLP-1 Drugs

The rationale for combining the two pathways is that amylin and GLP-1 both reduce food intake but through partly distinct neural circuits. In principle, engaging both could produce more weight loss than either alone at tolerable doses. That hypothesis is what the CagriSema program was designed to test.

Cagrilintide Research

Cagrilintide on Its Own

A phase 2 dose-finding trial in adults with overweight or obesity compared several once-weekly cagrilintide doses with placebo and with daily liraglutide 3.0 mg over 26 weeks. Weight loss increased with dose, and the highest cagrilintide doses produced more weight loss than placebo. Gastrointestinal effects were the most common adverse events, as expected for a satiety-acting peptide. These results established cagrilintide as an active agent in its own right, not only a combination partner.

CagriSema: Cagrilintide Plus Semaglutide

CagriSema pairs cagrilintide with semaglutide, with the phase 3 program studying cagrilintide 2.4 mg and semaglutide 2.4 mg given together once weekly. The phase 3 REDEFINE program has evaluated the combination in adults with obesity and in people with obesity and type 2 diabetes, including comparisons against each component alone.

Reported results have shown greater mean weight loss with the combination than with semaglutide or cagrilintide alone. As with every cross-trial comparison in this class, how the combination compares with tirzepatide or retatrutide can't be settled by setting headline numbers from separate trials side by side. Differences in populations, trial duration and titration schedules all affect those figures. For those comparisons, see retatrutide vs tirzepatide vs semaglutide.

What Remains Unknown

• Long-term outcomes. Cardiovascular and other hard-outcome data of the kind now available for semaglutide are not yet established for cagrilintide.
• Durability after stopping. Weight regain after discontinuation is well documented for the incretin class. Whether amylin co-therapy changes that pattern is not established.
• Lean mass. How much of the weight lost is fat versus lean tissue, and whether that differs from GLP-1 monotherapy, is an open question across the class.

Safety Profile

What Trials Have Reported

The adverse-event pattern reported for cagrilintide resembles that of other satiety-acting peptides:

These labels describe relative frequency in published and announced trial reports, not incidence rates for any individual patient. Gradual dose escalation is the standard approach to gastrointestinal tolerability across the class.

Class Considerations

In combination with semaglutide, the GLP-1 class warnings apply to the combination: thyroid C-cell tumors in rodent studies (the approved GLP-1 products are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2), pancreatitis, gallbladder disease, and dehydration from gastrointestinal losses. Hypoglycemia risk rises when these agents are used with insulin or sulfonylureas. Our weight-loss peptide safety guide covers monitoring across the class.

Regulatory Status and Access

Not FDA-Approved

Cagrilintide is investigational. There is no FDA-approved cagrilintide product, either alone or in combination with semaglutide, at the time of writing. Regulatory timelines for CagriSema should be checked against current announcements from the manufacturer and the FDA rather than assumed.

No Established Compounding Pathway

Cagrilintide does not appear on our FDA peptide status tracker, and we are not aware of an FDA determination making it eligible for 503A compounding. The reasoning in our retatrutide compounding guide applies here too: an investigational substance that is not a component of an FDA-approved drug, not on the 503A bulks list, and without a USP monograph has no established basis for legitimate 503A compounding.

Material sold online as "research" cagrilintide sits outside that framework. Its identity, purity, sterility and concentration can't be assumed, and there is no pharmacovigilance behind it. Patients who ask about cagrilintide today are usually better served by a conversation about FDA-approved options: semaglutide or tirzepatide.

Where Cagrilintide Fits

For now, cagrilintide is a compound to understand rather than to prescribe. It shows where obesity pharmacology is heading: combining hormonal pathways, as tirzepatide did with GIP and as retatrutide does with glucagon, to get more weight loss at tolerable doses. For the full landscape of weight-loss peptides and how each is positioned, see our guide to the best peptides for weight loss and fat loss.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner. Prescribers can start at For Providers.

Frequently Asked Questions

What is cagrilintide?

Cagrilintide is an investigational, long-acting analogue of amylin, a pancreatic hormone that slows gastric emptying, suppresses post-meal glucagon and promotes satiety. It is designed for once-weekly subcutaneous injection and is being studied for chronic weight management.

Is cagrilintide FDA-approved?

No. At the time of writing there is no FDA-approved cagrilintide product, alone or combined with semaglutide. Check current FDA and manufacturer announcements for the latest status.

What is CagriSema?

CagriSema is an investigational once-weekly combination of cagrilintide and semaglutide. Its phase 3 program (REDEFINE) has reported greater weight loss with the combination than with either component alone.

How is cagrilintide different from semaglutide?

Semaglutide mimics GLP-1 and acts on the GLP-1 receptor. Cagrilintide mimics amylin and acts on amylin and calcitonin receptors. The two pathways reduce food intake through partly different brain circuits, which is the rationale for combining them.

Can cagrilintide be compounded?

We are not aware of an established 503A pathway. Cagrilintide is investigational and does not appear on our FDA peptide status tracker. Material sold online as "research" cagrilintide is outside the regulated compounding framework.

What are the side effects of cagrilintide?

Trials have reported mainly gastrointestinal effects, such as nausea, constipation, diarrhea and vomiting, concentrated during dose escalation. Combined with semaglutide, the GLP-1 class warnings also apply.